Genesis Capital still can’t get an appointment to see the dentist.
Street Talk understands the board of the $310 million dental chain is set to reject Genesis’ revised “best and final” $1.95-per-share offer after two days of deliberations – $1.9825 if you include the October dividend.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
